The biggest source of capital for biotech is no longer venture capital but family offices, he saysThe biotech industry is in its own microcosm, unaffected by geopolitics, says Peter Kash, executive chairman of Camelot BioCapital. PHOTO: CAMELOT BIOCAPITAL[SINGAPORE] Biotech has become one of the few industries “immune” to current geopolitical tensions between China and the US, said Peter Kash, chairman of biotech venture studio Camelot BioCapital. Even so, he believes access to US capital markets remains critical for biotech companies seeking to raise public capital or achieve successful exits. Special purpose acquisition companies (Spac) could be helpful for Singapore biotech firms, Kash said. The biggest source of capital for biotech is no longer venture capital but family offices, he noted.